Botox injection for overactive bladder and neurological conditions

Botox is a prescription injection containing onabotulinumtoxinA, used to treat various conditions related to muscle overactivity and glandular secretions. It works by blocking nerve signals to muscles or glands, reducing symptoms in disorders such as overactive bladder, spasticity, chronic migraine, and excessive sweating.

Botox is approved for the following uses:

• Treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency who have not responded adequately or are intolerant to anticholinergic medicines.
• Treatment of urinary incontinence caused by detrusor overactivity related to neurologic conditions (e.g., spinal cord injury, multiple sclerosis) in adults who are inadequate responders or intolerant to anticholinergics.
• Treatment of neurogenic detrusor overactivity in pediatric patients aged 5 years and older who have inadequate response or intolerance to anticholinergic medication.
• Prevention of headaches in adults with chronic migraine (≥15 headache days per month with headache lasting 4 hours or more).
• Treatment of spasticity in patients aged 2 years and older.
• Treatment of cervical dystonia in adults to reduce abnormal head position and neck pain.
• Treatment of severe primary axillary hyperhidrosis (excessive underarm sweating) in adults when topical agents are insufficient.
• Treatment of blepharospasm associated with dystonia in patients 12 years and older.
• Treatment of strabismus in patients 12 years and older.

Limitations: Botox is not established as safe or effective for episodic migraine prophylaxis (less than 15 headache days/month), hyperhidrosis outside the axillary region, or axillary hyperhidrosis in patients under 18 years old. It has not shown improvement in upper limb function or joint range in spasticity with fixed contractures.

onabotulinumtoxinA

Botox contains onabotulinumtoxinA, which blocks the release of the neurotransmitter acetylcholine at nerve endings. By preventing acetylcholine release, it temporarily inhibits muscle contractions or glandular secretions in the injected area. This neuromuscular blockade reduces symptoms such as muscle spasticity, urinary urgency, excess sweating, and migraine headaches.

General dosing and administration

• Do not exceed a total dose of 400 Units in adults or 10 Units/kg (max 340 Units) in pediatric patients within a 3-month interval.
• Reconstitution must be done with sterile, preservative-free 0.9% Sodium Chloride Injection only.
• Administer using appropriate needle size and injection technique based on the indication.

Overactive bladder in adults

• 100 Units injected intradetrusor at 20 sites, 0.5 mL (5 Units) per injection, avoiding the trigone area.
• Patients should not have urinary tract infection at time of treatment.
• Consider prophylactic antibiotics (except aminoglycosides) 1-3 days before and after injection to reduce infection risk.
• Re-treatment considered when clinical effect diminishes, but no sooner than 12 weeks after previous injection.

Detrusor overactivity associated with neurologic condition in adults

• 200 Units injected intradetrusor at 30 sites, ~6.7 Units (1 mL) per injection, avoiding the trigone.
• Prophylactic antibiotics recommended as for overactive bladder.
• Re-treatment interval at least 12 weeks with median re-treatment time about 42-48 weeks.

Detrusor overactivity associated with neurologic condition in pediatric patients (≥5 years)

• For patients ≥34 kg: 200 Units intradetrusor injection.
• For patients <34 kg: 6 Units/kg body weight intradetrusor injection.
• Injection at 20 sites intradetrusor muscle; observe appropriate precautions regarding anesthesia or sedation based on age.

Chronic migraine

• 155 Units total dose injected intramuscularly at 31 sites divided among 7 specific head/neck muscles.
• Each injection is 0.1 mL (5 Units) using sterile 30-gauge, 0.5 inch needle; a longer needle may be required for thick neck muscles.
• Re-treatment typically every 12 weeks.

Spasticity

• Adults: up to 400 Units divided among affected muscles.
• Pediatric upper limb spasticity: 3-6 Units/kg (max 200 Units).
• Pediatric lower limb spasticity: 4-8 Units/kg (max 300 Units).
• Dosing tailored to size, location, severity, muscle weakness, and prior response; do not exceed 50 Units per injection site generally.

Cervical dystonia

• Dose individualized based on head/neck position, pain localization, muscle size, response history.
• Lower initial doses recommended for botulinum toxin treatment-naïve patients.

Primary axillary hyperhidrosis

• 50 Units injected per axilla.
• Only for severe cases inadequate controlled by topical treatments.

Blepharospasm and strabismus

• Blepharospasm: 1.25 to 2.5 Units into each of 3 sites per affected eye.
• Strabismus: dose based on prism diopter correction or prior response.

None explicitly stated in supplied evidence.

Boxed warning: Distant spread of toxin effect

Postmarketing data reveal that Botox effects may spread beyond the injection site, causing symptoms such as generalized muscle weakness, difficulty swallowing or breathing, double vision, eyelid drooping, and urinary incontinence. These effects can occur hours to weeks after injection and may be life-threatening, including rare reports of death. The risk is higher in children treated for spasticity but can also occur in adults, especially those with preexisting conditions that predispose them to such symptoms.

Additional warnings

• Do not exceed recommended doses or injection intervals.
• Use caution when injecting near lungs, especially in patients with respiratory compromise.
• Patients should not have active urinary tract infection at time of bladder treatment.
• Monitor for adverse reactions such as swallowing or breathing difficulties.
• Proper injection technique and knowledge of anatomy are critical.

Common side effects

• Injection site pain, swelling, or bruising
• Urinary tract infections (in bladder injections)
• Muscle weakness near injection site
• Headache and neck pain (in migraine treatment)
• Dry mouth or eye symptoms (in ocular treatments)

Serious side effects

• Distant spread of toxin effects causing muscle weakness, dysphagia, breathing difficulties
• Urinary retention requiring catheterization
• Allergic reactions including anaphylaxis

Concurrent use of aminoglycoside antibiotics or other agents interfering with neuromuscular transmission may potentiate Botox effects and increase risk of muscle weakness. Prophylactic antibiotics used during bladder treatment should avoid aminoglycosides. Patients on antiplatelet or anticoagulant therapy require management to reduce bleeding risk before injection.

Overdose may cause symptoms related to excessive muscle weakness or botulinum toxin effects including swallowing and breathing difficulties. Supportive medical management should be provided.

Store Botox as a vacuum-dried powder. After reconstitution with preservative-free 0.9% Sodium Chloride Injection, use within 24 hours stored refrigerated at 2° to 8°C. Discard any unused portion as vials are single-use only.